DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Election/Restrictions
Applicant’s election of Group I in the reply filed on 10/8/2026 is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.01(a)).
Specification
The following guidelines illustrate the preferred layout for the specification of a utility application. These guidelines are suggested for the applicant’s use.
Arrangement of the Specification
As provided in 37 CFR 1.77(b), the specification of a utility application should include the following sections in order. Each of the lettered items should appear in upper case, without underlining or bold type, as a section heading. If no text follows the section heading, the phrase “Not Applicable” should follow the section heading:
(a) TITLE OF THE INVENTION.
(b) CROSS-REFERENCE TO RELATED APPLICATIONS.
(c) STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT.
(d) THE NAMES OF THE PARTIES TO A JOINT RESEARCH AGREEMENT.
(e) INCORPORATION-BY-REFERENCE OF MATERIAL SUBMITTED ON A READ-ONLY OPTICAL DISC, AS A TEXT FILE OR AN XML FILE VIA THE PATENT ELECTRONIC SYSTEM.
(f) STATEMENT REGARDING PRIOR DISCLOSURES BY THE INVENTOR OR A JOINT INVENTOR.
(g) BACKGROUND OF THE INVENTION.
(1) Field of the Invention.
(2) Description of Related Art including information disclosed under 37 CFR 1.97 and 1.98.
(h) BRIEF SUMMARY OF THE INVENTION.
(i) BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWING(S).
(j) DETAILED DESCRIPTION OF THE INVENTION.
(k) CLAIM OR CLAIMS (commencing on a separate sheet).
(l) ABSTRACT OF THE DISCLOSURE (commencing on a separate sheet).
(m) SEQUENCE LISTING. (See MPEP § 2422.03 and 37 CFR 1.821 - 1.825). A “Sequence Listing” is required on paper if the application discloses a nucleotide or amino acid sequence as defined in 37 CFR 1.821(a) and if the required “Sequence Listing” is not submitted as an electronic document either on read-only optical disc or as a text file via the patent electronic system.
When there are drawings, there shall be a “brief description of the several views of the drawings” (See 37 C.F.R. 1.74.).
The section heading “brief description of the several views of the drawings” as set forth in 37 C.F.R. 1.74 is missing. Please correct.
Claim Objections
Claim 13 objected to because of the following informalities:
The phrase “thin stillage, vinasse” is missing the term “and”. Applicant is advised to consider stating “thin stillage and vinasse”.
The phrase “[t]he method … the method further comprises” in claim 15 is objected to because the language is redundant. Applicant is advised to consider stating “[t]he method … further comprises”.
Appropriate correction is required.
Claim Rejections - 35 USC § 112
The following is a quotation of 35 U.S.C. 112(b):
(b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.
The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph:
The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
Claims 1-18 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention.
The phrase “genetically changed genomes” in claim 1, line 1 is vague and indefinite as it is unclear what is the basis of ascertaining the change.
Claim 1 is vague and indefinite as it unclear what is being processed to produce a biomass as the claim starts with culturing an unspecified material with the “genetically changed genomes” language. Since it is unclear what is being processed the rest of the claim and the dependent claims are unclear.
The phrase “non-metabolizable glucose analogue” in claim 1, line 3 is vague and indefinite as it is unclear what is the basis of this language as it appears whether it is metabolizable depends on the organism tested.
The term “improved” in claim 1, line 6 is a relative term which renders the claim indefinite. The term “improved” is not defined by the claim, the specification does not provide a standard for ascertaining the requisite degree, and one of ordinary skill in the art would not be reasonably apprised of the scope of the invention. A person having ordinary skill in the art could interpret strains as improved while another could interpret the same strains as not improved.
Claim 1 recites the limitation "the cultured genetically changed genomes" in lines 5-6. There is insufficient antecedent basis for this limitation in the claim. Applicant is advised to consider earlier stating "cultured genetically changed genomes".
Claim 1 recites the limitation "the isolated improved fungal strains" in line 7. There is insufficient antecedent basis for this limitation in the claim. Applicant is advised to consider earlier stating "isolated improved fungal strains".
Claim 1 recites the limitation "the pre-cultivated improved fungal strains" in line 8. There is insufficient antecedent basis for this limitation in the claim. Applicant is advised to consider earlier stating "pre-cultivated improved fungal strains".
Claim 4 recites the limitation "the content" in line 2. There is insufficient antecedent basis for this limitation in the claim. Applicant is advised to consider stating "a content".
The phrase “xylo-, malto-, cello-, and raffinose-derived oligosaccharides” in claim 6, line 3 is vague and indefinite as it is unclear what these are and whether they are the material or contained within a larger material.
Claim 9 recites the limitation "the filamentous fungus" in line 2. There is insufficient antecedent basis for this limitation in the claim. Applicant is advised to consider earlier stating "filamentous fungus".
Claim 1 recites the limitation "the pre-cultivated improved fungal strains" in line 8. There is insufficient antecedent basis for this limitation in the claim. Applicant is advised to consider earlier stating "pre-cultivated improved fungal strains".
Claim 10 recites the limitation "fermentation is a batch fermentation" in line 2. There is insufficient antecedent basis for this limitation in the claim. It appears Applicant is attempting to further limit a “fermentation” in claim 1, however, a fermentation is not set forth in claim 1. Claim 10 does not further limit any claim.
Claim 11 recites the limitation "fermentation is a continuous fermentation" in line 2. There is insufficient antecedent basis for this limitation in the claim. It appears Applicant is attempting to further limit a “fermentation” in claim 1, however, a fermentation is not set forth in claim 1. Claim 11 does not further limit any claim.
Claim 12 recites the limitation "the dilution rate" in line 1. There is insufficient antecedent basis for this limitation in the claim. Applicant is advised to consider stating "a dilution rate".
Claim 16 recites the limitation "drying" in line 2. There is insufficient antecedent basis for this limitation in the claim. Applicant is advised to consider stating "the drying".
A broad range or limitation together with a narrow range or limitation that falls within the broad range or limitation (in the same claim) may be considered indefinite if the resulting claim does not clearly set forth the metes and bounds of the patent protection desired. See MPEP § 2173.05(c). In the present instance, claim 18 recites the broad recitation “Paecilomyces variotii”, and the claim also recites “Paecilomyces variotii strain KCL-24” which is the narrower statement of the range/limitation. The claim(s) are considered indefinite because there is a question or doubt as to whether the feature introduced by such narrower language is (a) merely exemplary of the remainder of the claim, and therefore not required, or (b) a required feature of the claims.
Clarification and/or correction required.
Claim Rejections - 35 USC § 102
The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention.
Claim(s) 1-18 is/are rejected under 35 U.S.C. 102(a)(2) as being anticipated by Huang et al. (US 2014/0004560).
The claims are not interpreted as processing any specific material per the “genetically changed genomes” language in claim 1, line 1, thus, a method of processing an unknown product is not a method having any tangible method limitations.
Regarding claims 1-18, Huang (‘560) teaches a method of producing fungal biomass (See As., paras. 8, 11, 19, 28-29 and claims.).
Conclusion
Any inquiry concerning this communication or earlier communications from the examiner should be directed to BRENT T O'HERN whose telephone number is (571)272-6385. The examiner can normally be reached M-Th 5:00 am - 3:30 pm.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Emily Le can be reached at 571-272-0903. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/BRENT T O'HERN/ Primary Examiner, Art Unit 1793
October 12, 2026